Aug 10, 2026 02:33AM
Aug 10, 2026 02:32AM
Aug 10, 2026 02:30AM
Aug 10, 2026 02:30AM
Aug 10, 2026 02:00AM
Aug 10, 2026 02:00AM
May 13, 2026 01:00AM Innate Pharma Reports First Quarter 2026 Business Update and Financial Results
Mar 26, 2026 02:00AM
Nov 13, 2025 01:00AM
Nov 10, 2025 01:01AM
Nov 10, 2025 01:00AM
Oct 23, 2025 07:10AM
Oct 14, 2025 01:00AM
Sep 17, 2025 01:00AM Innate Pharma Reports First Half 2025 Business Update and Financial Results
May 23, 2025 01:00AM
May 13, 2025 01:00AM
Apr 16, 2025 01:00AM
Mar 27, 2025 02:00AM
Feb 17, 2025 01:02AM
Jan 21, 2025 01:00AM
Dec 9, 2024 01:00AM Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma
Dec 3, 2024 01:00AM
Nov 13, 2024 01:00AM
Sep 23, 2024 01:00AM
Sep 12, 2024 01:00AM
Jun 17, 2024 01:00AM
Jun 4, 2024 01:00AM
May 21, 2024 01:00AM Innate Pharma: Clarification Regarding SAR443579 Designation
May 14, 2024 01:00AM
Apr 15, 2024 01:00AM
Mar 21, 2024 02:00AM
Jan 4, 2024 05:10AM
Jan 4, 2024 01:00AM
Dec 11, 2023 03:43AM
Dec 11, 2023 01:00AM Innate Pharma Shares Efficacy and Safety Phase 1 /2 Results of NK Cell Engager SAR443579 / IPH6101 Developed by Sanofi at ASH 2023
Dec 10, 2023 01:00AM
Nov 27, 2023 01:00AM
Nov 14, 2023 01:00AM
Oct 5, 2023 04:48AM
Oct 5, 2023 01:00AM
Sep 22, 2023 01:00AM
Sep 14, 2023 01:00AM Innate Pharma Reports First Half 2023 Financial Results and Business Update
Jun 16, 2023 06:05AM
Jun 16, 2023 01:00AM
Jun 12, 2023 01:00AM
Jun 8, 2023 01:00AM
Jun 8, 2023 01:00AM
Dec 10, 2022 10:00AM
Nov 4, 2022 02:00AM Innate Pharma to Present Results From a Preliminary Analysis of the TELLOMAK Phase 2 Trial in Patients With Advanced Sezary Syndrome and ANKET™ Platform at ASH 2022
Mar 18, 2021 02:00AM

328,603 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All